Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
- Frédéric Chibon 1, Pauline Lagarde , Sébastien Salas , Gaëlle Pérot , Véronique Brouste , Franck Tirode , Carlo Lucchesi , Aurélien de Reynies , Audrey Kauffmann , Binh Bui , Philippe Terrier , Sylvie Bonvalot , Axel Le Cesne , Dominique Vince-Ranchère , Jean-Yves Blay , Françoise Collin , Louis Guillou , Agnès Leroux , Jean-Michel Coindre , Alain Aurias
- 1Département de Pathologie, Institut Bergonié, Bordeaux, France. chibon@bergonie.org
- 0Département de Pathologie, Institut Bergonié, Bordeaux, France. chibon@bergonie.org
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new gene expression signature, CINSARC, accurately predicts sarcoma metastasis risk. This genomic approach improves upon traditional grading, potentially guiding more targeted sarcoma treatments and reducing patient harm.
Area Of Science
- Oncology
- Genomics
- Cancer Biology
Background
- Sarcomas are aggressive mesenchymal tumors with histological grading limitations.
- Current grading methods show moderate reproducibility and variable prognostic value for certain sarcoma types.
Purpose Of The Study
- To develop a more accurate prognostic tool for sarcoma patients.
- To establish a gene expression signature for predicting metastasis-free survival in sarcomas.
Main Methods
- Genomic and expression profiling of 183 sarcomas for training.
- Development of a 67-gene prognostic signature, CINSARC (complexity index in sarcomas).
- Validation of CINSARC in an independent set of 127 sarcomas.
Main Results
- CINSARC accurately predicts metastasis outcome in both training and validation sets.
- The CINSARC signature outperforms the Fédération Francaise des Centres de Lutte Contre le Cancer grading system.
- CINSARC also demonstrates prognostic value in gastrointestinal stromal tumors (GISTs), breast carcinomas, and lymphomas.
Conclusions
- The CINSARC gene expression signature offers superior prognostic capability for sarcomas compared to current methods.
- This signature can enable more selective adjuvant therapy application, minimizing iatrogenic morbidity.
- Improved patient stratification through CINSARC can lead to better overall outcomes for individuals with sarcomas and other cancers.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.